PanamaTuberculosis profile
Population  2015 3.9 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.24 (0.22–0.25) 6.1 (5.6–6.5)
Mortality (HIV+TB only) 0.039 (<0.01–0.14) 1 (0.03–3.5)
Incidence  (includes HIV+TB) 2 (1.5–2.5) 50 (38–63)
Incidence (HIV+TB only) 0.23 (0.17–0.29) 5.7 (4.3–7.3)
Incidence (MDR/RR-TB)** 0.089 (0.055–0.12) 2.3 (1.4–3.1)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.083 (0.044–0.12) 0.59 (0.3–0.87) 0.67 (0.35–0.99)
Males 0.079 (0.05–0.11) 1.2 (0.91–1.5) 1.3 (0.96–1.6)
Total 0.16 (0.11–0.21) 1.8 (1.5–2.1) 2 (1.5–2.5)
TB case notifications, 2015  
Total cases notified 1 658
Total new and relapse 1 566
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 89%
          - % pulmonary 83%
          - % bacteriologically confirmed among pulmonary 62%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 80% (64–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.14 (0.1–0.2)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 195 14%
          - on antiretroviral therapy 184 94%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  59
(38–80)
Estimated % of TB cases with MDR/RR-TB 3% (1.5–4.6) 12% (6.9–17)  
% notified tested for rifampicin resistance 21% 35% 650
MDR/RR-TB cases tested for resistance to second-line drugs   9
Laboratory-confirmed cases MDR/RR-TB: 34, XDR-TB: 1
Patients started on treatment **** MDR/RR-TB: 34, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 79% 1 483
Previously treated cases, excluding relapse, registered in 2014 49% 97
HIV-positive TB cases, all types, registered in 2014 68% 178
MDR/RR-TB cases started on second-line treatment in 2013 50% 4
XDR-TB cases started on second-line treatment in 2013   0
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
100% (100–100)
TB financing, 2016  
National TB budget (US$ millions) 3
Funding source: 62% domestic, 26% international, 12% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-10 Data: www.who.int/tb/data